69-44-3
69-44-3 结构式
基本信息
盐酸阿莫他喹
盐酸阿莫地喹
阿莫地喹盐酸盐
阿莫地喹二盐酸盐
阿莫他喹二盐酸盐
7-氯-4-(3'-二乙基氨基甲基-4'-羟基苯胺基)喹啉二盐酸盐
4-((7-氯喹啉-4-基)氨基)-2-((二乙胺基)甲基)苯酚二盐酸盐
camoquinhydrochloride
AMODIAQUIN HYDROCHLORIDE
Acrichin dihydrochloride
AMODIAQUINE HYDROCHLORIDE
AMODIAQUIN DIHYDROCHLORIDE
AMODIAQUINE DIHYDROCHLORIDE
BULK DRUG : AMODIAQUINE HYDROCHLORIDE (DMF GRADE)
4-((7-chloro-4-quinolyl)amino)-alpha-(diethylamino)-o-cresodihydrochloride
4-((7-chloro-4-quinolyl)amino)-alpha-(diethylamino)-o-cresoldihydrochloride
常见问题列表
2. 与三硅酸镁和白陶土同时服用，氯喹胃肠吸收下降，阿莫地喹可能同氯喹相同。
3. 皮下注射狂犬病疫苗的同时服用氯喹预防疟疾时，可能会干扰抗体的产生。在使用阿莫地喹时应考虑。
阿莫地喹的临床前研究就估计到了它的诱变和遗传毒性效应。细菌诱变的实验报告显示，对沙门菌属的诱变作用很弱，但对妊娠期服用阿莫地喹的剂量还没有研究，也就没有引起器官和结构畸形的数据资料。有资料显示，在妊娠期服用氯喹后出现了几例先天畸形（法洛四联症、先天性甲状腺功能减退、脉络膜视网膜炎耳聋），氯喹能通过胎盘屏障，阿莫地喹可能也可以通过，但在妊娠期使用阿莫地喹药物没有发现先天畸形。尽管这样，有研究者认为妊娠期应禁用阿莫地喹。而其他的研究者认为即使没有足够的资料显示阿莫地喹的安全 性，但是在没有找到可替代的药物之前不应该限制它的使用。WHO 也认识到了阿莫地喹的毒性，但没有在妊娠期禁用阿莫地喹的数据，因此需要进一步的研究。
EC50: ~20 μM (Nurr1-LBD (ligand binding domain))
Histamine N-methyltransferase
Amodiaquine (10-20 μM; 4 hours) treatment suppresses LPS-induced expression of proinflammatory cytokines (IL-1β, interleukin-6, TNF-α and iNOS) in a dose-dependent manner.
Amodiaquine (5 μM; 24 hours) significantly inhibits neurotoxin (6-OHDA-induced cell death in primary dopamine cells as examined by the number of TH
+
neurons and dopamine uptake. The neuroprotective effect of Amodiaquine is also observed in rat PC12 cells.
RT-PCR
| Cell Line: | Primary microglia |
| Concentration: | 10 µM, 15 µM, 20 µM |
| Incubation Time: | 4 hours |
| Result: | Suppressed LPS-induced expression of proinflammatory cytokines (IL-1β, interleukin-6, TNF-α and iNOS) in a dose-dependent manner. |
Amodiaquine (40 mg/kg; intraperitoneal injection; daily; for 3 days; male ICR mice) treatment diminishes perihematomal activation of microglia/macrophages and astrocytes. Amodiaquine also suppresses ICH-induced mRNA expression of IL-1β, CCL2 and CXCL2, and ameliorated motor dysfunction of mice.
| Animal Model: | Male ICR mice (8-10 weeks of age) induced ntracerebral hemorrhage (ICH) |
| Dosage: | 40 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 3 days |
| Result: | Diminished perihematomal activation of microglia/macrophages and astrocytes. |